Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma

Blood

Volumn 122, Issue 2, 2013, Pages 219-226

  Kaiser, Martin F ^a,b   Johnson, David C ^a   Wu, Ping ^a   Walker, Brian A ^a   Brioli, Annamaria ^a,c   Mirabella, Fabio ^a   Wardell, Christopher P ^a   Melchor, Lorenzo ^a   Davies, Faith E ^a   Morgan, Gareth J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CELLULAR RETINOL BINDING PROTEIN 1; GLUTATHIONE PEROXIDASE 3; OSTEONECTIN; TRANSFORMING GROWTH FACTOR BETA1; AZACITIDINE; DRUG DERIVATIVE; SPARC PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOGENETICS; DNA METHYLATION; EPIGENETICS; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNATIONAL STAGING SYSTEM SCORE; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCORING SYSTEM; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; CHROMOSOME ABERRATION; DISEASE COURSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; MIDDLE AGED; MORTALITY; PHENOTYPE; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AZACITIDINE; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PHENOTYPE; PROGNOSIS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR SUPPRESSOR PROTEINS;

EID: 84884494098     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-487884     Document Type: Article

References (50)

1. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335-348.
2. Walker BA, Wardell CP, Chiecchio L, et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood. 2011;117(2):553-562.
3. Fonseca R, Bergsagel PL, Drach J, et al; International Myeloma Working Group. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210-2221.
4. Kim JH, Karnovsky A, Mahavisno V, et al. LRpath analysis reveals common pathways dysregulated via DNA methylation across cancer types. BMC Genomics. 2012;13:526.
5. Deneberg S, Guardiola P, Lennartsson A, et al. Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. Blood. 2011;118(20):5573-5582.
6. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13(7):484-492.
7. Raynal NJ, Si J, Taby RF, et al. DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res. 2012;72(5):1170-1181.
8. Kulis M, Heath S, Bibikova M, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012;44(11):1236-1242.
9. Berman BP, Weisenberger DJ, Aman JF, et al. Regions of focal DNA hypermethylation and longrange hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet. 2012;44(1):40-46.
10. Heller G, Schmidt WM, Ziegler B, et al. Genomewide transcriptional response to 5-aza-29- deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res. 2008;68(1):44-54. (Pubitemid 351380104)
11. de Carvalho F, Colleoni GW, Almeida MS, Carvalho AL, Vettore AL. TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. Int J Cancer. 2009;125(8):1985-1991.
12. Mateos MV, García-Sanz R, López-Pérez R, et al. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol. 2002;118(4):1034-1040. (Pubitemid 35025966)
13. Gonzalez-Paz N, Chng WJ, McClure RF, et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood. 2007;109(3):1228-1232. (Pubitemid 46220672)
14. Jung S, Kim S, Gale M, et al. DNA methylation in multiple myeloma is weakly associated with gene transcription. PLoS ONE. 2012;7(12):e52626.
15. Morgan GJ, Davies FE, Gregory WM, et al; National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376(9757):1989-1999.
16. Morgan GJ, Graham J, Davies FE, et al. Longterm follow-up of patients with multiple myeloma receiving bisphosphonates in conjunction with antimyeloma therapy: MRC Myeloma IX study. 17th Congress of European Hematology Association. June 14-17, 2012. Amsterdam.
17. Boyd KD, Ross FM, Chiecchio L, et al; NCRI Haematology Oncology Studies Group. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012;26(2):349-355.
18. Dickens NJ, Walker BA, Leone PE, et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res. 2010;16(6): 1856-1864.
19. Ernst J, Kheradpour P, Mikkelsen TS, et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature. 2011; 473(7345):43-49.
20. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007; 12(2):131-144. (Pubitemid 47208626)
21. Chen L, Wang S, Zhou Y, et al. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood. 2010;115(1):61-70.
22. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12(2):115-130. (Pubitemid 47199123)
23. Fulciniti M, Amin S, Nanjappa P, et al. Significant biological role of sp1 transactivation in multiple myeloma. Clin Cancer Res. 2011;17(20): 6500-6509.
24. Tsai HC, Li H, Van Neste L, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012;21(3):430-446.
25. Vaidyanathan G, Cismowski MJ, Wang G, Vincent TS, Brown KD, Lanier SM. The Rasrelated protein AGS1/RASD1 suppresses cell growth. Oncogene. 2004;23(34):5858-5863. (Pubitemid 39093032)
26. Nojima M, Maruyama R, Yasui H, et al. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clin Cancer Res. 2009;15(13): 4356-4364.
27. Wen G, Partridge MA, Li B, et al. TGFBI expression reduces in vitro and in vivo metastatic potential of lung and breast tumor cells. Cancer Lett. 2011;308(1):23-32.
28. Ahmed AA, Mills AD, Ibrahim AE, et al. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell. 2007;12(6): 514-527. (Pubitemid 350199074)
29. Wang N, Zhang H, Yao Q, Wang Y, Dai S, Yang X. TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer. J Exp Clin Cancer Res. 2012;31:6.
30. Davies FE, Dring AM, Li C, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood. 2003;102(13):4504-4511. (Pubitemid 37494117)
31. Chetty C, Dontula R, Gujrati M, Dinh DH, Lakka SS. Blockade of SOX4 mediated DNA repair by SPARC enhances radioresponse in medulloblastoma. Cancer Lett. 2012;323(2): 188-198.
32. Bhoopathi P, Gorantla B, Sailaja GS, et al. SPARC overexpression inhibits cell proliferation in neuroblastoma and is partly mediated by tumor suppressor protein PTEN and AKT. PLoS ONE. 2012;7(5):e36093.
33. Lehmann S, O'Kelly J, Raynaud S, Funk SE, Sage EH, Koeffler HP. Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia. 2007;21(9):1931-1936. (Pubitemid 47299966)
34. Said N, Frierson HF, Sanchez-Carbayo M, Brekken RA, Theodorescu D. Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J Clin Invest. 2013;123(2):751-766.
35. Pellagatti A, Jädersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA. 2007;104(27): 11406-11411. (Pubitemid 47175153)
36. Wang H, Luo K, Tan LZ, et al. p53-induced gene 3 mediates cell death induced by glutathione peroxidase 3. J Biol Chem. 2012;287(20): 16890-16902.
37. Chen B, Rao X, House MG, Nephew KP, Cullen KJ, Guo Z. GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response. Cancer Lett. 2011;309(1):37-45.
38. Yu YP, Yu G, Tseng G, et al. Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res. 2007;67(17):8043-8050. (Pubitemid 47395138)
39. Wang S, Tricot G, Shi L, et al. RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood. 2009;114(3): 600-607.
40. Lavelle D, Chen YH, Hankewych M, Desimone J. Inhibition of myeloma cell growth by all-trans retinoic acid is associated with upregulation of p21WAF1 and dephosphorylation of the retinoblastoma protein. Leuk Lymphoma. 1999; 35(3-4):261-268.
41. Sanda T, Iida S, Kayukawa S, Ueda R. Induction of class II major histocompatibility complex expression in human multiple myeloma cells by retinoid. Haematologica. 2007;92(1):115-120. (Pubitemid 46232665)
42. Guo Y, Pino-Lagos K, Ahonen CA, et al. A retinoic acid-rich tumor microenvironment provides clonal survival cues for tumor-specific CD8(1) T cells. Cancer Res. 2012;72(20):5230-5239.
43. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: a decade later. Blood. 2011;118(13):3470- 3478.
44. Hundemer M, Klein U, Hose D, et al. Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transplant. 2007;40(11):1033-1037. (Pubitemid 350142555)
45. Sahara N, Takeshita A. Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens. Leuk Lymphoma. 2004; 45(1):61-65. (Pubitemid 38181394)
46. Pellat-Deceunynck C, Barill é S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12(12):1977-1982. (Pubitemid 28554471)
47. Taberlay PC, Kelly TK, Liu CC, et al. Polycombrepressed genes have permissive enhancers that initiate reprogramming. Cell. 2011;147(6): 1283-1294.
48. Vicente-Duenãs C, Romero-Camarero I, González-Herrero I, et al. A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors. EMBO J. 2012; 31(18):3704-3717.
49. Kikushige Y, Ishikawa F, Miyamoto T, et al. Selfrenewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell. 2011;20(2): 246-259.
50. Dominguez-Sola D, Victora GD, Ying CY, et al. The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. Nat Immunol. 2012;13(11):1083-1091.